Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 36, Issue 9, 2005, Pages 803-811

  Morita, Y ^a,b   Hosokawa, M ^a   Ebisawa, M ^c   Sugita, T ^b   Miura, O ^b   Takaue, Y ^a   Heike, Y ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c SRL INC   (Japan)

Author keywords

CMV; CTL; HLA A*02; HLA A*24; HSCT

Indexed keywords

BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; EPITOPE; FLUDARABINE; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA A24 ANTIGEN; TETRAMER;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; MAJOR CLINICAL STUDY; MALE; MONITORING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEROTYPE; SOLID TUMOR; T CELL LEUKEMIA; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADULT; AGED; ANTIGENS, VIRAL; CELLS, CULTURED; CYTOMEGALOVIRUS; EPITOPES, T-LYMPHOCYTE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-A ANTIGENS; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; NEOPLASMS; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 27744558609     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705133     Document Type: Article

References (36)

1. Boeckh M, Nichols WG, Papanicolaou G et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543-558.
2. Cwynarski K, Ainsworth J, Cobbold M et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 1232-1240.
3. Gratama JW, van Esser JW, Lamers CH et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98: 1358-1364.
4. Gratama JW, Cornelissen JJ. Clinical utility of tetramer-based immune monitoring in allogeneic stem cell transplantation. Biodrugs 2003; 17: 325-338.
5. Gratama JW, Cornelissen JJ. Diagnostic potential of tetramer-based monitoring of cytomegalovirus-specific CD8+ T lymphocytes in allogeneic stem cell transplantation. Clin Immunol 2003; 106: 29-35.
6. Heijnen IA, Barnett D, Arroz MJ et al. Enumeration of antigen-specific CD8(+) T lymphocytes by single-platform, HLA tetramer-based flow cytometry: A European multicenter evaluation. Cytometry 2004; 62B: 1-13.
7. Engstrand M, Tournay C, Peyrat MA et al. Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 2000; 69: 2243-2250.
8. Singhal S, Shaw JC, Ainsworth J et al. Direct visualization and quantitation of cytomegalovirus-specific CD8+ cytotoxic T-lymphocytes in liver transplant patients. Transplantation 2000; 69: 2251-2259.
9. Lacey SF, Diamond DJ, Zaia JA. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant 2004; 10: 433-447.
10. Longmate J, York J, La Rosa C et al. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001; 52: 165-173.
11. Tokunaga K, Ishikawa Y, Ogawa A et al. Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics 1997; 46: 199-205.
12. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999; 50: 201-212.
13. Kuzushima K, Hayashi N, Kimura H, Tsurumi T. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001; 98: 1872-1881.
14. Akiyama Y, Maruyama K, Mochizuki T et al. Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus. Immunol Lett 2002; 83: 21-30.
15. Akiyama Y, Kuzushima K, Tsurumi T, Yamaguchi K. Analysis of HLA-A24-restricted CMVpp65 peptide-specific CTL with HLA-A(*)2402-CMVpp65 tetramer. Immunol Lett 2004; 95: 199-205.
16. Provenzano M, Mocellin S, Bettinotti M et al. Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells. J Immunother 2002; 25: 342-351.
17. Provenzano M, Lim JB, Mocellin S et al. The matrix protein pp65(341-350): A peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele. Transfusion 2003; 43: 1567-1574.
18. Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996; 157: 2539-2548.
19. Kang X, Kawakami Y, el-Gamil M et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol 1995; 155: 1343-1348.
20. Rauser G, Einsele H, Sinzger C et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004; 103: 3565-3572.
21. Retiere C, Lesimple B, Lepelletier D et al. Association of glycoprotein B and immediate early-1 genotypes with human leukocyte antigen alleles in renal transplant recipients with cytomegalovirus infection. Transplantation 2003; 75: 161-165.
22. Masuoka M, Yoshimuta T, Hamada M et al. Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes. Viral Immunol 2001; 14: 369-377.
23. Burrows SR, Elkington RA, Miles JJ et al. Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: Biological validation of the proposed HLA A24 supertype. J Immunol 2003; 171: 1407-1412.
24. Lacey SF, Villacres MC, La Rosa C et al. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 2003; 64: 440-452.
25. Hoffmeister B, Kiecker F, Tesfa L et al. Mapping T cell epitopes by flow cytometry. Methods 2003; 29: 270-281.
26. Kern F, Bunde T, Faulhaber N et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002; 185: 1709-1716.
27. Maecker HT, Dunn HS, Suni MA et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001; 255: 27-40.
28. Kern F, Faulhaber N, Frommel C et al. Analysis of CD8T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000; 30: 1676-1682.
29. Karlsson AC, Martin JN, Younger SR et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 2003; 283: 141-153.
30. Hobeika AC, Morse MA, Osada T et al. Enumerating antigen-specific T-cell responses in peripheral blood: A comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 2005; 28: 63-72.
31. Godard B, Gazagne A, Gey A et al. Optimization of an elispot assay to detect cytomegalovirus-specific CD9+ T lymphocytes. Hum Immunol 2004; 65: 1307-1318.
32. Mohty M, Mohty AM, Blaise D et al. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen. Bone Marrow Transplant 2004; 33: 839-846.
33. Sun Y, Iglesias E, Samri A et al. A systematic comparison of methods to measure HIV-1 specific CD8T cells. J Immunol Methods 2003; 272: 23-34.
34. Livingston BD, Crimi C, Fikes J et al. Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules. Hum Immunol 1999; 60: 1013-1017.
35. Szmania S, Galloway A, Bruorton M et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 2001; 98: 505-512.
36. Watanabe N, Kamachi Y, Koyama N et al. Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale: A simple culture system using tetrameric HLA-peptide complexes. Cytotherapy 2004; 6: 514-522.